Johnson & Johnson (NYSE:JNJ) – Equities research analysts at Jefferies Group lowered their FY2018 earnings per share estimates for Johnson & Johnson in a research note issued to investors on Thursday. Jefferies Group analyst J. Holford now forecasts that the firm will post earnings of $7.16 per share for the year, down from their previous estimate of $7.30. Jefferies Group currently has a “Hold” rating and a $115.00 target price on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2019 earnings at $7.80 EPS and FY2020 earnings at $8.52 EPS.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Other research analysts also recently issued reports about the company. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price target on the stock in a report on Friday, August 5th. Wells Fargo & Co. reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 11th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective for the company in a research report on Monday, August 22nd. Deutsche Bank AG reissued a “buy” rating and issued a $142.00 price objective on shares of Johnson & Johnson in a research report on Friday, August 19th. Finally, Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a research report on Sunday, September 11th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $120.20.

Shares of Johnson & Johnson (NYSE:JNJ) opened at 117.56 on Monday. Johnson & Johnson has a 52 week low of $94.28 and a 52 week high of $126.07. The stock has a market capitalization of $321.63 billion, a PE ratio of 21.91 and a beta of 0.62. The company has a 50-day moving average price of $118.72 and a 200 day moving average price of $117.37.

In related news, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the sale, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Americafirst Capital Management LLC purchased a new position in Johnson & Johnson during the second quarter valued at $101,000. Tuttle Tactical Management LLC purchased a new position in Johnson & Johnson during the second quarter valued at $103,000. Lenox Wealth Management Inc. raised its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares during the last quarter. Thomas J. Herzfeld Advisors Inc. raised its position in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares during the last quarter. Finally, NCM Capital Management Group Inc. purchased a new position in Johnson & Johnson during the second quarter valued at $127,000. 65.32% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.